Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-2344

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-2344). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2344 3)

Label for Losartan Potassium 100 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label shows a quantity of 30 tablets and is marked Rx Only. It includes barcodes, NDC 68071-2344-3, and storage instructions to keep at 68-77°F. The manufacturer is Metro Labs Limited, Mahabubnagar, India. The label also contains warnings to keep out of reach of children and advises contacting a doctor for side effect information.*

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period for Atenolol and Losartan potassium. The x-axis represents study months from 0 to 60, and the y-axis represents the percentage of patients with the primary endpoint up to 16%. The graph shows adjusted risk reduction of 13% with a p-value of 0.021 favoring Losartan potassium.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

Line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan Potassium. The graph shows increasing stroke rates over time, with Losartan Potassium associated with a lower percentage of patients affected. The graph includes a note on adjusted risk reduction of 25% and a p-value of 0.001.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A forest plot figure showing primary endpoint events within demographic subgroups comparing Losartan Potassium and Atenolol event rates. The chart presents hazard ratios with 95% confidence intervals for primary composite events and stroke (fatal/non-fatal) across subgroups defined by age, gender, race, isolated systolic hypertension (ISH), diabetes status, and cardiovascular disease history. The plot visually indicates which treatment favors each subgroup.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

A line graph comparing the percentage of patients experiencing an event over 48 months, with one line representing Losartan Potassium and the other representing a placebo. The graph shows a gradual increase in event percentage for both groups, with Losartan Potassium consistently having a lower percentage than placebo. The chart includes statistical information indicating a risk reduction of 16.1% and a p-value of 0.022.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure of losartan potassium showing its molecular arrangement with chlorine, hydroxyl, and potassium groups attached to the core molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.